OncoAlert

🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨

[OncoAlert @OncoAlert]

OncoAlert Round Up🚨 Day 4 of #ASCO26
For More, REGISTER TO THE NEWSLETTER 👉https://t.co/Ou3rJ6A8W6

Today's highlights span ADCs, radioligand therapy, immunotherapy, cellular therapy, breast, GU, thoracic, GI oncology, and supportive care.

🔹 ABBV-706: 52% ORR in relapsed/refractory SCLC
🔹 EMERALD-3: STRIDE + TACE improves outcomes in unresectable HCC
🔹 POTOMAC: 5-year DFS benefit with durvalumab + BCG in NMIBC
🔹 ALCHEMIST: Adjuvant nivolumab misses DFS endpoint in NSCLC
🔹 PSMAddition: Earlier ^177Lu-PSMA-617 improves rPFS in mHSPC
🔹 Oral SERDs show class benefit, especially in ESR1-mutant disease
🔹 IMbrave251 supports TKI monotherapy after atezo-bev progression
🔹 Bupropion shows benefit for cancer-related fatigue
Plus: important insights on post-progression therapies and interpretation of OS endpoints.
Read today's full roundup and stay current with the studies shaping future cancer care.

@StephenVLiu
@RenoHemonc
@HHorinouchi
@Tony_Calles
@lungoncdoc
@Dr_Oncologista
@NReguart
@LaurenByersMD
@rachnatshroff
@OncBrothers
@NiuSanford
@DraMartinezLago
@ArndtVogel
@GlopesMd
@LorenzaRimassa
@MichaelMayMD
@DrVilmaPBarcia
@jgong15
@tompowles1
@BethN01
@DrChoueiri
@nataliagandur
@katy_beckermann
@shimoi_oncology
@mjuanfi81
@YGaritaonaindia
@DrRiyazShah
@zklaassen_md
@CalaisJeremie
@RKSayyid
@ErikaHamilton9
@drnurullahilhan
@DFCI_BreastOnc
@kazuki_nozawa

#OncoAlert #Oncology #MedTwitter #ASCO #CancerResearch

[Uromigos @Uromigos]

The adjuvant RAMPART trial by James Larkin opens new areas of debate in the adjuvant renal cancer field. #ASCO26 https://t.co/IjcRiOrlNF

[Uromigos @Uromigos]

Listen to our podcast on RAS inhibition here!

https://t.co/r6vJdGGpad

[Brian Rini, MD @brian_rini]

Podcast with @neerajaiims here:

https://t.co/MHD8ibl9Tl

[Vanita Noronha, MBBS MD DM @VanitaNoronha]

Link to the article: https://t.co/hHmmLxM4hl
@drakhilkapoor1 @Nandinimenon18 @minitjshah @OncoAlert @Amolpatel_dr @montypal @neerajaiims

[Hidehito HORINOUCHI @HHorinouchi]

🔥14-protein plasma signature predicts lung cancer >5 years before diagnosis
🆙 @CellCellPress
☑Analysis of 48,000+ samples; validated across 8 cohorts
🎯Anti-IL-1β therapy stratified by signature lowers NNT for prevention
🎙Dr. Tej Pandya @CharlesSwanton
#LCSM @O@OncoAlert @Larvol
https://t.co/a5W8m67pqX

[Erman Akkus @Erman_Akkus]

🏥T4, MRF, CRM in rectal cancer for medical oncologists

✅All related but different concepts
➡️T4b but MRF- (e.g. upper third tm)
➡️MRF by MRI, CRM by pathological
➡️MRF- but CRM+ (e.g. technically hard surgery)

PS: prepared by AI. Surgeon, pathologist, radiologist colleagues may correct if wrong

#cancer #oncology #MedX #rectal #GI @OncoAlert

[Mario Balsa @MarioBalsaMD]

📚 New review! Targeted therapy in BRAF-mutant melanoma: advances and challenges
https://t.co/hPwThwovFR

🎯 BRAF/MEK combos reshaped melanoma care
💥 Long-term benefit, but resistance remains the rule
🧬 Key culprits: MAPK reactivation, MITF plasticity & phenotype switching
🤔 Next step? Smarter sequencing + combinations

We know how to block BRAF, melanoma keeps teaching us how not to get BRAF-fled🧬

@OncoAlert
@OncoReporte @myESMO @_SEOM

[Mario Balsa @MarioBalsaMD]

📄 Insight of immune checkpoint blockades in melanoma (review)!
https://t.co/qGiejbBZvp

🧬 Comprehensive overview of PD-1, CTLA-4, LAG-3, TIGIT and emerging checkpoint pathways
🔍 Mechanisms of response, resistance and immune escape
🎯 Highlights biomarkers and personalized IO strategies
💥 A roadmap for the next generation of melanoma IO

Checkpoint by checkpoint, learning that the biggest barrier isn’t the blockade itself…it’s what slips through the checkpoints 🔓🧠#Melanoma #Immunotherapy #PD1 #CTLA4 #TIGIT #LAG3

@OncoAlert
@OncoReporte @myESMO @_SEOM

[Hidehito HORINOUCHI @HHorinouchi]

🔥Prognostic impact of molecular alterations in resected lung adeno & implications for TNM 10th edition
🆙 @JTOonline
☑EGFR, TP53, KRAS & ALK
🎯TP53/KRAS: potential potential in stage I
🎯ALK: downstaging potential in stages III–IV
🎙Dr. Huatao Tang
#LCSM @OncoAlertncoAlert @Larvol @EGFRResisters @ALKPositiveinc @KRASKickers
https://t.co/UNa4E3H8vK

[Hidehito HORINOUCHI @HHorinouchi]

🔥Phase 1: ABBV-706 (SEZ6-targeting ADC) in R/R SCLC & solid tumors
🆙 @NatureMedicine
☑R/R SCLC; ORR 52%; mOS 12.4 mo at RP2D
🎯RP2D confirmed at 1.8 mg/kg Q3W balancing efficacy & safety
🎙 @LaurenByersMD
#LCSM @OncoAlert @Larvol
https://t.co/vjUUd1GYSy

[Jame Abraham, MD, FACP @jamecancerdoc]

Excellent article @NimaSharifiMD an outstanding clinician scientist- my friend and collaborator @NEJM how fasting or a fasting mimicking diet can augment the effects of hormonal therapy in breast cancer @OncoAlert @theNCI

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Delighted to share our paper:
“Axillary management in patients with cN + breast cancer undergoing neoadjuvant chemotherapy: pattern of practice in Italy”🇮🇹✨

🔗 https://t.co/wCRn7wYZo2
@OncoAlert #OncoAlertAF #ctRO

👉🏻 A nationwide survey exploring current practices in axillary management of clinically node-positive (cN +) breast cancer patients undergoing neoadjuvant chemotherapy, among Italian #RadOnc

#BreastCancer @ESTRO_RT @FiorenzaDe @MariaCarmenDeS1 @PriscoA78 @PasinettiNadia @samydic86 @brunomeduri @riccardo_ray @IsabellaPalum10 @Icro_Meattini @Pier_Franco_MD @EdyIppolito

[Uğur Özkerim @UOzkerim]

ASTRUM-005 long-term follow-up continues to impress in ES-SCLC.

✅ Median OS: 15.8 vs 11.1 months
✅ OS HR: 0.60
✅ 4-year OS: 21.9% vs 7.2%
✅ PFS HR: 0.47

Perhaps the most striking finding is the durable survival plateau beyond 3 years, reinforcing the potential of PD-1 blockade plus platinum-etoposide in extensive-stage SCLC.@JAMAOnc
@OncoAlert @StephenVLiu @RManochakian @GlopesMd @ManuelDomine @weoncologists @OncoReporte @MedwatchKate @Larvol @LungCancerEu
👇
https://t.co/4Hn5kzEx2m

[Ainhoa Madariaga @AinhoaMada]

Happy to share our @AACR Cancer review of #ADCs in #GynecologicCancers #gyncsm
📍From approved ADCs to those on development
❗Resistance & sequencing
⏩ Toxicity management

Free access 👇 https://t.co/UPKQ2c0Rtw

@ArantzazuBarqu1
@LKasherman @StephanieLheur5 @OncoAlert

[Jose Fernando Moura, PhD @FernandoOnco]

Are we revolutionizing 🫁 cancer screening?
A 14-protein plasma signature predicted 🫁 cancer risk more than 5 y before diagnosis and identified who may benefit from IL-1β targeted prevention.
Early detection may soon become early interception @OncoAlert
https://t.co/3BUCJGfcWh

[ACS Journal Cancer @JournalCancer]

🧠 As the week wraps up, #CancerScope looks at research published in JAMA linking stereotactic radiation to fewer symptoms and improved quality of life for patients with 5–20 brain metastases.

Section Editor Dr. Helen Shih offers commentary:
https://t.co/HM0Mn5vAo8

@OncoAlert

[ACS Journal Cancer @JournalCancer]

New findings led by @UR_Med & @WilmotCancer researchers suggest that hyperphosphatemia may serve as a potential biomarker of erdafitinib activity among patients with advanced urothelial cancer and warrant prospective validation.

https://t.co/Vo3hcBlyuV

@OncoAlert #uroonc

[JAMA Oncology @JAMAOnc]

A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. https://t.co/JehoSISuhO

[Alessandro Di Federico @DiFedericoMD]

What does chemo add to immunotherapy in pts w/ PD-L1-high NSCLC?
In our meta-analysis of 24 trials w/ reconstructed individual patient data, we observed a meaningful improvement in both median PFS (11.3 vs 6.8 months, HR 0.74) and OS (29.2 vs 19.8 months, HR 0.67) w/ chemo-ICI.

[CA: A Cancer Journal for Clinicians @CACancerJournal]

ICYMI: New Phase 3 study from @ESTRO_RT @EORTC_BCG: Nodal irradiation for breast cancer decreases breast-cancer related mortality but increases non-breast cancer related mortality after 22.2 years in @EORTC trial 22922/10925.

Read the full open report:
https://t.co/neUoXljorn